Completed OBSERVATIONAL NCT01940198

Long-term Atazanavir Experience in a High HIV Caseload Primary Care Practice in Sydney, Australia (REfLecT)

Sponsor: Bristol-Myers Squibb

Conditions HIV

Updated 6 times since 2017 Last updated: Sep 8, 2013 Started: Apr 30, 2010 Primary completion: Aug 31, 2011 Completion: Sep 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01940198, this observational or N/A phase trial focuses on HIV and remains completed. Sponsored by Bristol-Myers Squibb, it has been updated 6 times since 2010, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None

▶ Show 1 earlier version

Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Apr 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bristol-Myers Squibb
Holdsworth House Medical Practice

Data source: Holdsworth House Medical Practice

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Sydney, Australia